Key result
Dronedarone prolonged the time to atrial fibrillation recurrence to 60-158 days compared with 5-59 days with placebo, but may increase mortality in patients with congestive heart failure.
Why the study?
Does dronedarone improve time to atrial fibrillation recurrence and decrease heart rate in patients with atrial fibrillation?
Population
Patients with atrial fibrillation (and animal models)
Comparison
Dronedarone vs Placebo
Design
Review
Authors
Loading...
Urges HF mortality caution with dronedarone; leaves open net benefit pending higher-level trials.
Does dronedarone improve time to atrial fibrillation recurrence and decrease heart rate in patients with atrial fibrillation?
Dronedarone is a novel antiarrhythmic agent that prolongs time to atrial fibrillation recurrence and reduces heart rate, though it carries risks of gastrointestinal side effects, proarrhythmia, and increased mortality in heart failure patients.
Dale et al. (2007) conducted a review in Atrial fibrillation. Dronedarone vs. Placebo was evaluated on Time to atrial fibrillation recurrence. Dronedarone prolonged the time to atrial fibrillation recurrence to 60-158 days compared with 5-59 days with placebo, but may increase mortality in patients with congestive heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: